Breast cancer in octogenarian women: Clinical characteristics and outcome


Kuzan T., Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., ...More

Journal of B.U.ON., vol.18, no.2, pp.328-334, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 2
  • Publication Date: 2013
  • Title of Journal : Journal of B.U.ON.
  • Page Numbers: pp.328-334
  • Keywords: breast cancer, elderly, octogenarian, outcome, treatment, TUMOR CHARACTERISTICS, ELDERLY-WOMEN, AGED 80, CARCINOMA, OLDER, MORTALITY, SURVIVAL, ESTROGEN, RADIOTHERAPY

Abstract

Purpose: Breast cancer incidence increases in the elderly but data on treatment and outcomes of elderly patients is limited. We assessed the clinicopathological features and outcomes of our patients with breast cancer aged ≥80 years in comparison with their younger postmenopausal counterparts. Methods: The records of 83 patients diagnosed with breast cancer after the age of 80 (group 1) between 2003 and 2011 in 4 different centers were retrospectively evaluated and the clinicopathological features and outcomes were assessed in comparison with a control group (group 2) of 249 patients aged between 60-70 years. Results: Median ages at diagnosis were 82 years (range 80-95) and 64 years (range 60-70) for group 1 and group 2, respectively. The incidence of invasive cancers other than ductal or lobular type was higher in group 1 than in group 2 (20 vs 8%; p=0.017). More patients in group 1 had Charlson Comorbidty scores ≥1 than those in group 2 (49 vs 36%; p=0.011). Patients in group 1 had more conservative operations and less axillary node dissections (ALND) and they received chemotherapy, trastuzumab or radiotherapy less frequently compared to their younger counterparts in group 2. Median follow up period was 36 months (range 1-178) in group 1 and 24 months (range 12-217) in group 2. Five-year disease free survival (DFS) was 53.7 and 75.9% (p=0.005), 5-year overall survival (OS) was 61.9% and 80.4% in group 1 and group 2 (p=0.001), respectively. Advanced stage (stage IV vs stage I, II, III, p=0.051) and cerbB2 positivity (p<0.001) were found to be associated with shorter DFS in patients ≥80 years of age. Conclusion: Although the majority of patients were undertreated in our study according to the current guidelines, mortality rates were quite low. Different biology of the disease in the elderly might explain this difference.